AlphaGrep UK Ltd’s ResMed RMD Stock Holding History

AlphaGrep UK Ltd’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$584K	Buy	2,603 +189	+8%	+$47.1K	0.17%	171
2025 Q4	$581K	Buy	+2,414	New	+$617K	0.19%	162

Other funds holding RMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

DAM

Diamant Asset Management Ridgefield, Connecticut $147M AUM 25.76% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

AlphaGrep UK Ltd's RMD Position: Q1 2026 in Review

AlphaGrep UK Ltd increased its ResMed (RMD) stake by 7.8% in Q1 2026, buying an estimated $47.1K and bringing the position to 2,603 shares worth $584K. The position accounts for 0.17% of the portfolio, ranked #171.

AlphaGrep UK Ltd first reported a position in RMD in Q4 2025 and has held it in 2 quarters since. 941 funds tracked by Wall St. Rank hold RMD as of Q1 2026.

AlphaGrep UK Ltd held 2,603 shares of ResMed worth $584K as of Q1 2026.
AlphaGrep UK Ltd bought 189 ResMed shares in Q1 2026, an estimated $47.1K.
ResMed made up 0.17% of AlphaGrep UK Ltd's portfolio in Q1 2026, its #171 holding.
AlphaGrep UK Ltd first reported a position in ResMed in Q4 2025 and has held it in 2 quarters since.
941 funds tracked by Wall St. Rank held ResMed as of Q1 2026.

Based on AlphaGrep UK Ltd's 13F filing for Q1 2026, filed 13 Aug 2026.